Wellstat Vaccines, LLC (Wellstat) is engaged in discovering and developing therapeutic vaccines. The company is developing vaccine candidates for meningitis serogroup B, C and Y, group A and B streptococcus, haemophilus influenzae type B, pneumococcus, candida and aspergillus. Wellstat develops its products based on synthetic or semisynthetic, conjugate carbohydrate technology. Its candida is expected to provide long-lasting immunity against vaginal yeast infections, and systemic candidiasis. Group A Streptococcus vaccine is expected to provide immunity against strep throat (pharyngitis) and impetigo (skin infection). Group B Streptococcus (GBS) vaccine is expected to provide immunity against sepsis, pneumonia, and meningitis among newborns. Meningococcus B synthetic vaccine has the potential to provide immunity against meningococcal disease. Wellstat is headquartered in Gaithersburg, Maryland, the US.